Retinoic acid receptor antagonists as promoters of angiogenesis
AssigneeBristol-Myers Squibb Company
InventorsVioletta Iotzova, Peter Reczek
Life of this patent
Estimating the term…
Abstract
Methods and compositions for treating various disorders by administering a therapeutically effective amount of a retinoic acid receptor antagonist alone or in combination or in conjunction with other therapeutic agents to promote angiogenesis are provided. Also provided are methods for obtaining additional retinoic acid receptor antagonists for use as therapeutic agents to promote angiogenesis.
Claims22
A method of promoting angiogenesis in a mammal comprising administering to the mammal an effective amount of a retinoic acid receptor triple antagonist, wherein the mammal has scleroderma or cardiovascular disease, or has been subjected to solid organ transplant.
A method of promoting angiogenesis in a mammal having bone fracture comprising administering to the mammal an effective amount of a retinoic acid receptor triple antagonist that exhibits less than 50% agonism.
A method of treating a disease or condition in a mammal by administering an effective amount of a retinoic acid receptor triple antagonist, wherein said disease or condition is selected from the group consisting of scleroderma, cardiovascular disease, and solid organ transplant.
A method of treating bone fracture in a mammal by administering an effective amount of a retinoic acid receptor triple antagonist that exhibits less than 50% agonism.
A method of treating a disease or condition in a mammal comprising administering to the mammal an effective amount of a retinoic acid receptor triple antagonist, wherein said disease or condition is selected from the group consisting of venous or diabetic ulcer or ischemia, and wherein the retinoic acid triple antagonist is selected from the group consisting of (E)-4-[[(5,6-dihydro-5,5-dimethyl-8-phenylethynyl)-2-naphthalenyl]ethenyl]benzoic acid, (E)-4-[2-[5,6-dihydro-5,5-dimethyl-8-(2naphthalenyl)-2-naphthalenyl]ethenyl]-benzoic acid, and (E)-4-[2-[5,6-dihydro-5,5-dimethyl-8-(4methoxyphenyl)-2-naphthalenyl]ethenyl]benzoic acid.
Dependencies are inferred from the claim text.